MCID: CRV002
MIFTS: 48

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 70
Cervical Intraepithelial Neoplasia 44 70
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 70
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8991
ICD9CM 34 233.1
MeSH 44 D018290
SNOMED-CT 67 92564006
ICD10 32 D06 D06.9
UMLS 70 C0206708 C0851140 C2987516

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology : 12 An uterus carcinoma in situ that is located in the uterine cervix.

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and human papillomavirus infectious disease. An important gene associated with Cervix Uteri Carcinoma in Situ is MIR548B (MicroRNA 548b), and among its related pathways/superpathways are Glioblastoma Multiforme and Senescence and Autophagy in Cancer. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include uterine cervix, cervix and uterus.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 cervicitis 31.4 SERPIND1 GP6 GP5 CDKN2A
2 human papillomavirus infectious disease 31.2 TP53 FHIT CDKN2A
3 cervical intraepithelial neoplasia 31.0 KRT17 FHIT CDKN2A
4 vaginal cancer 30.9 TP53 INSM1 GP5 CDKN2A
5 anus cancer 30.7 TP53 GP6 GP5 CDKN2A
6 chronic cervicitis 30.5 TP53 SERPIND1 KRT17 GP6 GP5 CDKN2A
7 cervical squamous cell carcinoma 30.5 TP53 KRT17 CDKN2A
8 squamous cell papilloma 30.5 TP53 GP5 CDKN2A
9 vulvar intraepithelial neoplasia 30.4 TP53 CDKN2A
10 endocervical adenocarcinoma 30.3 TP53 INSM1 CDKN2A
11 vulva cancer 30.3 TP53 GP5 CDKN2A
12 cervical incompetence 30.3 PTPRN INSM1
13 keratinizing squamous cell carcinoma 30.3 TP53 CDKN2A
14 epidermodysplasia verruciformis 1 30.3 TP53 GP6 GP5
15 oropharynx cancer 30.1 TP53 GP6 GP5 CDKN2A
16 in situ carcinoma 30.1 TP53 MIR654 MIR548B LCOR KRT17 CDKN2A
17 cervical cancer 30.0 TP53 RUBCNL RB1 FHIT CDKN2A
18 suppressor of tumorigenicity 3 29.9 TP53 RB1 FHIT CDKN2A
19 cervix carcinoma 29.7 TP53 PTPRN INSM1 GP5 FHIT CDKN2A
20 anogenital venereal wart 29.6 TP53 RB1 GP6 GP5 CDKN2A
21 cervix disease 29.4 TP53 PTPRN MIR338 LCOR INSM1 GP5
22 chlamydia 10.8
23 squamous cell carcinoma 10.7
24 immune deficiency disease 10.6
25 bacterial vaginosis 10.6
26 vaginal discharge 10.6
27 adenocarcinoma 10.5
28 retinoblastoma 10.5
29 vaginitis 10.4
30 47,xyy 10.4
31 herpes simplex 10.4
32 early invasive cervical adenocarcinoma 10.4 INSM1 CDKN2A
33 human immunodeficiency virus type 1 10.3
34 adenosquamous carcinoma 10.3
35 placenta disease 10.3
36 papillary squamous carcinoma 10.3 INSM1 CDKN2A
37 esophagus verrucous carcinoma 10.3 TP53 CDKN2A
38 ovarian seromucinous carcinoma 10.3 TP53 CDKN2A
39 spitz nevus 10.3 TP53 CDKN2A
40 cervical adenocarcinoma 10.3
41 48,xyyy 10.3
42 focal epithelial hyperplasia 10.3 GP6 GP5
43 bizarre leiomyoma 10.3 TP53 CDKN2A
44 basosquamous carcinoma 10.3 TP53 KRT17
45 adult malignant schwannoma 10.3 TP53 CDKN2A
46 comedo carcinoma 10.3 TP53 LCOR GP5
47 supraglottis cancer 10.3 TP53 CDKN2A
48 large cell acanthoma 10.3 TP53 KRT17
49 localized osteosarcoma 10.3 TP53 CDKN2A
50 malignant exocrine pancreas neoplasm 10.3 TP53 CDKN2A

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Adenomyosis Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
4 Vaccines Phase 4
5 Monophosphoryl lipid A Phase 4
6 Adrenergic alpha-Agonists Phase 4
7 Adrenergic Agonists Phase 4
8 Vasoconstrictor Agents Phase 4
9 Adrenergic beta-Agonists Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Epinephryl borate Phase 4
12 Respiratory System Agents Phase 4
13 Sympathomimetics Phase 4
14 Mydriatics Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic Agents Phase 4
17 Anesthetics, Local Phase 4
18 Bronchodilator Agents Phase 4
19
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
20
Fluorouracil Approved Phase 3 51-21-8 3385
21
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
22
Aluminum sulfate Approved Phase 3 10043-01-3
23
Eugenol Approved Phase 3 97-53-0 3314
24
acetic acid Approved Phase 3 64-19-7 176
25
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
26
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
27
Fenretinide Investigational Phase 3 65646-68-6
28 Immunoglobulins Phase 3
29 Antibodies Phase 3
30 Immunosuppressive Agents Phase 3
31 Antimetabolites Phase 3
32 Retinamide Phase 3
33 Olive Phase 3
34 Sodium Channel Blockers Phase 3
35 Anti-Arrhythmia Agents Phase 3
36 Diuretics, Potassium Sparing Phase 3
37
Retinol acetate Phase 3 127-47-9 10245972
38 Immunologic Factors Phase 3
39 Anesthetics Phase 3
40 Adjuvants, Immunologic Phase 3
41 interferons Phase 3
42 Raspberry Approved Phase 2
43
Masoprocol Approved, Investigational Phase 1, Phase 2 27686-84-6, 500-38-9 71398
44
BCG vaccine Approved, Investigational Phase 2
45
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
46
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
47
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
48
Eflornithine Approved, Withdrawn Phase 2 70052-12-9 3009
49
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
50
Catechin Approved, Withdrawn Phase 2 154-23-4 9064

Interventional clinical trials:

(show top 50) (show all 274)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Completed NCT03629886 Phase 4
4 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Completed NCT03105856 Phase 4
5 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
6 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
7 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
8 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
9 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
10 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
11 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Unknown status NCT03366493 Phase 3
12 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
13 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
14 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
15 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
16 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
17 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
18 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
19 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
20 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
21 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
22 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
23 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
24 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
25 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
26 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
27 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
28 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
29 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
30 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
31 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
32 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
33 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
34 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
35 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
36 DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Multicenter, Prospective Cohort Study Recruiting NCT04646954 Phase 3
37 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
38 A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years Active, not recruiting NCT04537156 Phase 3
39 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
40 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
41 A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. Not yet recruiting NCT03848039 Phase 3 Placebo
42 A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) Not yet recruiting NCT04484415 Phase 3
43 Safety and Efficacy of Two Screen-and-Treat Approaches for the Prevention of Cervical Cancer Terminated NCT00233727 Phase 3
44 TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial. Terminated NCT02329171 Phase 3 Imiquimod
45 ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial Terminated NCT01283763 Phase 3 Topical Imiquimod
46 A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia Terminated NCT00529464 Phase 3
47 A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Unknown status NCT03745846 Phase 2
48 A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3) Unknown status NCT02596243 Phase 2
49 Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years Unknown status NCT02740777 Phase 2
50 Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III Unknown status NCT00060099 Phase 2

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Uteri Carcinoma in Situ:

19
Uterine Cervix

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

40
Cervix, Uterus, Endothelial, T Cells, Lymph Node, Nk Cells, Eye

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 8017)
# Title Authors PMID Year
1
Primary diaphragmatic clear cell carcinoma associated with endometriosis: A case report and literature review. 61
33665296 2021
2
In situ immunopathological events in human cervical intraepithelial neoplasia and cervical cancer: Review. 61
33677234 2021
3
miR-130a-3p promotes cell proliferation and invasion by targeting estrogen receptor α and androgen receptor in cervical cancer. 61
33747155 2021
4
Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women. 61
33252834 2021
5
Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. 61
33811457 2021
6
Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway. 61
33649833 2021
7
Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study. 61
33794208 2021
8
Management of low-grade cervical cytology in young women. Cohort study from Denmark. 61
33030976 2021
9
Cervical lesion assessment using real-time microendoscopy image analysis in Brazil: The CLARA study. 61
33811763 2021
10
Dynamic Spectral Imaging Colposcopy Versus Regular Colposcopy in Women Referred With High-Grade Cytology: A Nonrandomized Prospective Study. 61
33470739 2021
11
Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study. 61
33516531 2021
12
Follow-up After Loop Electrosurgical Excision of Cervical Intraepithelial Neoplasia: The Use of Combined Cytology and Human Papillomavirus Testing. 61
33660676 2021
13
Increases in Human Papillomavirus Testing Preceding Diagnosis of Cervical Precancer in 5 US States, 2008-2016. 61
33797511 2021
14
Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia. 61
33664804 2021
15
Expression profiles of metallothionein-I/II and megalin/LRP-2 in uterine cervical squamous lesions. 61
33084977 2021
16
Correction to: Loop Electrosurgical Excision Procedure Treats Cervical Intraepithelial Neoplasia 2/3 Among HIV- and HIV+ Women in Kenya. 61
33746197 2021
17
Prognostic outcomes and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study. 61
33394202 2021
18
Clinical Challenges in Managing Cervical Intraepithelial Neoplasia 2: A Report From a Cross-sectional Survey. 61
33631780 2021
19
DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population. 61
33300604 2021
20
Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study. 61
33121340 2021
21
Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017. 61
33035473 2021
22
The meaning of high-risk HPV other than type 16/18 in women with negative cytology: Is it really safe to wait for 1 year? 61
33528903 2021
23
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. 61
33492104 2021
24
Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study. 61
33661957 2021
25
Uptake and safety of community-based "screen-and-treat" with thermal ablation preventive therapy for cervical cancer prevention in rural Lilongwe, Malawi. 61
33687746 2021
26
DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. 61
33757653 2021
27
Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study. 61
33451725 2021
28
Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. 61
33566361 2021
29
Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. 61
33037625 2021
30
Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker. 61
33307803 2021
31
The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. 61
33559190 2021
32
High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests. 61
33728437 2021
33
Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix. 61
33808260 2021
34
Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesions. 61
33710792 2021
35
Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases. 61
33764649 2021
36
DNA ploidy measurement and human papillomavirus in abnormal cervical cytology. 61
33217061 2021
37
Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. 61
32895912 2021
38
Colposcopic Impression Has a Key Role in the Estimation of the Risk of HSIL/CIN3. 61
33799584 2021
39
Classification of high-grade CIN by p16ink4a , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management. 61
33729551 2021
40
Diagnosis of cervical precancerous lesions based on multimodal feature changes. 61
33440316 2021
41
p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. 61
32745170 2021
42
Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. 61
33006394 2021
43
Automatic acetowhite lesion segmentation via specular reflection removal and deep attention network. 61
33684051 2021
44
Options for triage and implications for colposcopists within European HPV-based cervical screening programmes. 61
33524777 2021
45
Human Papillomavirus Distribution in Women with Abnormal Pap Smear and/or Cervical Intraepithelial Neoplasia in Vaccination Era. A Single-Center Study in the North Italian Population. 61
33807458 2021
46
Association of cervicovaginal dysbiosis mediated HPV infection with cervical intraepithelial neoplasia. 61
33545325 2021
47
Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. 61
33795132 2021
48
Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients. 61
33754436 2021
49
Dihydroartemisinin administration improves the effectiveness of 5-aminolevulinic acid-mediated photodynamic therapy for the treatment of high-risk human papillomavirus infection. 61
33157332 2021
50
GRAND: A large-scale dataset and benchmark for cervical intraepithelial Neoplasia grading with fine-grained lesion description. 61
33690025 2021

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.63 TP53 RB1 CDKN2A
2 11.57 TP53 RB1 CDKN2A
3 11.46 TP53 RB1 FHIT
4 11.2 TP53 RB1 CDKN2A
5 10.84 TP53 RB1 CDKN2A
6 10.37 GP6 GP5
7 10.14 TP53 RB1 CDKN2A

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.43 TP53 RB1 CDKN2A
2 replicative senescence GO:0090399 9.37 TP53 CDKN2A
3 hemostasis GO:0007599 9.33 SERPIND1 GP6 GP5
4 negative regulation of CD4-positive, alpha-beta T cell proliferation GO:2000562 9.32 LGALS7B LGALS7
5 apoptotic process GO:0006915 9.17 TP53 RB1 MAL LGALS7B LGALS7 FHIT
6 positive regulation of cell cycle arrest GO:0071158 9.13 TP53 INSM1 CDKN2A

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone deacetylase binding GO:0042826 9.43 TP53 LCOR INSM1
2 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
3 galactoside binding GO:0016936 8.96 LGALS7B LGALS7
4 disordered domain specific binding GO:0097718 8.8 TP53 RB1 CDKN2A

Sources for Cervix Uteri Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....